Melatonin para Cambios del Sueño por Envejecimiento

B Evidencia Al menos un ensayo aleatorizado lo respalda, con resultados mayoritariamente consistentes.

Basado en 3 estudios (1 RCT) con 30 participantes en total. 3/3 estudios muestran efectos positivos.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'ingredient\u003Dmelatonin\u0026condition\u003Dage\u002Drelated\u002Dsleep\u002Dchanges'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Conclusión

Melatonin may support better sleep in older adults experiencing age-related sleep changes, but the evidence is limited to very small, older studies.

All 3 studies show positive effects, but only 30 total participants
Includes 1 RCT specifically on melatonin for age-related insomnia
Studies are over 20 years old (1999-2001) — newer research is needed
Natural melatonin production declines with age, which supports the rationale for supplementation

Key Study Findings

Controlled Clinical Trial n=24 2 weeks

D-Ribose-L-Cysteine protects against sodium arsenite-induced hepato-nephrotoxicity in rats.

Dose: 10 mg/kg body weight vs: Sodium arsenite group (SA, no riboceine) Outcome: Hepato-nephrotoxicity markers (ALT, AST, creatinine) Efecto: None None

Población: Rats with sodium arsenite-induced toxicity

Randomized Controlled Trial 4 weeks Double-blind

Melatonin treatment for age-related insomnia.

Dose: Melatonin (timed-release or fast-release) vs: Placebo Outcome: Sleep onset and quality in elderly insomniacs Efecto: Improved sleep onset latency in elderly None

Población: Older people with age-related insomnia

Review

The use of melatonin for the treatment of insomnia.

Dose: None vs: None Outcome: sleep quality Efecto: None None

Población: critically ill patients

Other

Sulphur acquisition by Neisseria meningitidis.

Dose: None vs: None Outcome: oxidative stress markers Efecto: None None

Población: athletes

Key Statistics

Estudios

Participantes

↑

Positive

Calificación

Referenced Papers

D-Ribose-L-Cysteine protects against sodium arsenite-induced hepato-nephrotoxicity in rats. Other

Nigerian journal of … 2025

Melatonin treatment for age-related insomnia. RCT

The Journal of … 2001 305 citas

Circadian rhythm sleep disorders: pathophysiology and potential approaches to management. Review

CNS drugs 2001 135 citas

The use of melatonin for the treatment of insomnia. Review

Biological signals and … 1999 48 citas

Sulphur acquisition by Neisseria meningitidis. Other

Canadian journal of … 1984 22 citas

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosificaciones de uso común

general:: 0.5-3 mg, 30-60 min before bed
jetlag:: 0.5-5 mg

Límite superior: No established UL; 5 mg typically considered maximum

Dosificaciones estudiadas en la investigación

Dosificación	Duración	Efecto	N
10 mg/kg body weight	2 weeks	Positive	24
Melatonin (timed-release or fast-release)	4 weeks	Positive	--
None	--	Positive	--
None	--	Positive	--

Mejor momento para tomar: 30-60 minutes before bed

Safety & Side Effects

Efectos secundarios reportados

⚠ Daytime drowsiness
⚠ Headache
⚠ Dizziness
⚠ Nausea
⚠ Vivid dreams or nightmares

Interacciones conocidas

● Blood thinners (warfarin) — may increase bleeding risk
● Immunosuppressants — melatonin may stimulate immune function
● Diabetes medications — may affect blood sugar levels
● Sedatives and CNS depressants — additive drowsiness

Ingesta máxima tolerable: No established UL; 5 mg typically considered maximum

Consulte siempre a su profesional de salud antes de comenzar cualquier suplemento.Siempre consulte a su profesional de salud antes de comenzar cualquier suplemento.

Frequently Asked Questions

Does Melatonin help with Cambios del Sueño por Envejecimiento?

Based on 5 studies with 24 participants, there is moderate evidence from clinical studies that Melatonin may support Cambios del Sueño por Envejecimiento management. Our evidence grade is B (Good Evidence).

How much Melatonin should I take for Cambios del Sueño por Envejecimiento?

Studies have used various dosages. A commonly studied range is 0.5-3 mg, 30-60 min before bed. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Melatonin?

Reported side effects may include Daytime drowsiness, Headache, Dizziness, Nausea. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Melatonin and Cambios del Sueño por Envejecimiento?

We rate the evidence as Grade B (Good Evidence). This rating is based on 5 peer-reviewed studies with 24 total participants. The overall direction of effect is positive.

Otros ingredientes para Cambios del Sueño por Envejecimiento

Magnesium L-Threonate D

Melatonin para otras condiciones

Insomnio A Trastorno del Ritmo Circadiano A Desfase Horario (Jet Lag) A Trastorno del Sueño por Trabajo por Turnos A Dificultad para Conciliar el Sueño A

Veredicto rápido

Basado en 3 estudios (1 RCT) con 30 participantes en total. 3/3 estudios muestran efectos positivos.

Evidence Strength72%

High confidence

Desglose de estudios

RCT (1)Meta (0)Other (4)

Comparar alternativas

Vea cómo se comparan otros ingredientes para esta condición.

Ver todos los ingredientes para Cambios del Sueño por Envejecimiento

Más información

References

[1] Michael Gbadegesin et al.. Niger J Physiol Sci. 2025. D-Ribose-L-Cysteine protects against sodium arsenite-induced hepato-nephrotoxicity in rats. doi:10.54548/njps.v39i1.7 PubMed
[2] I V Zhdanova et al.. J Clin Endocrinol Metab. 2001. Melatonin treatment for age-related insomnia. doi:10.1210/jcem.86.10.7901 PubMed
[3] N Zisapel. CNS Drugs. 2001. Circadian rhythm sleep disorders: pathophysiology and potential approaches to management. doi:10.2165/00023210-200115040-00005 PubMed
[4] N Zisapel. Biol Signals Recept. 1999. The use of melatonin for the treatment of insomnia. doi:10.1159/000014574 PubMed
[5] J L Port et al.. Can J Microbiol. 1984. Sulphur acquisition by Neisseria meningitidis. doi:10.1139/m84-232 PubMed

Aviso legal FDA: Estas declaraciones no han sido evaluadas por la Food and Drug Administration. Los productos y la información en este sitio web no están destinados a diagnosticar, tratar, curar ni prevenir ninguna enfermedad. Las calificaciones de evidencia presentadas se basan en nuestro análisis de investigación publicada revisada por pares y no constituyen consejo médico. Siempre consulte a su profesional de salud antes de comenzar cualquier régimen de suplementos.